Vnitr Lek 2005, 51(2):245-248

Redakční pošta

B. Lačňák1, D. Stejskal2
1 Interní oddělení Nemocnice Šternberk
2 Oddělení laboratorní medicíny Nemocnice Šternberk

Received: December 20, 2004; Published: February 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lačňák B, Stejskal D. Redakční pošta. Vnitr Lek. 2005;51(2):245-248.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rodak BF. Diagnostic Hematology. Philadelphia: WB Saunders 1995.
    2. Reuter HD. The Platelet. Ahresburg: Labor Fibrintimer 1999.
    3. Petrželová A, Stejskal D, Prošková J et al. Initial experience with use of cationic propyl gallate as an inducer of thrombocyte aggregation in evaluation of anti-aggregation therapy. Vnitř Lék 2001; 47: 747-752. Go to PubMed...
    4. Schwartz KA, Schwartz DE, Davis JA. Detection and monitoring of aspirin inhibition of platelet function using the cationtic propyl gallate platelet aggregation assay. In: Abstract Book American Society of Hematology Meeting 1998: 17-19. Go to PubMed...
    5. Maly M, Vojacek J, Hadacova I et al. Assessment of speed of an anti-platelet effect after two different doses of acetylsalicylic acid by flocculation. Vnitř Lék 2004; 50: 428-433. Go to PubMed...
    6. Kvasnička J. Trombofilie a trombotické stavy v klinické praxi. Praha: Grada 2003.
    7. Pecka M. Přehled laboratorní hematologie IV. Praha: Galén 2000.
    8. Alexander JH, Harrrington RA, Title RH et al. Prior aspirin use predict worse outcomes in patiens with non-ST-elevation acute coronary syndromes. Am J Cardiol 1999; 83: 1147-1151. Go to original source... Go to PubMed...
    9. Pecka M, Malý J. Laboratorní hematologie. Hradec Králové: Credit 2004.
    10. Burtis CA, Ashwood ER. Tietz Textbook of Clinical Chemistry. Philadelphia: WB Saunders 1999.
    11. SI-jednotky: http://www.prevod.cz
    12. Gonzalez-Conejero R, Rivera J, Corral J et al. Biological Assessment of Aspirin Efficacy on Healthy Individuals. Heterogeneous Response or Aspirin Failure? Stroke 2004: (v tisku). Go to original source...
    13. Maree AO, Fitzgerald DJ. Aspirin and coronary artery disease. Thromb Haemost 2004; 92: 1175-1181. Go to original source... Go to PubMed...
    14. Pecka M, Malý J. Laboratorní hematologie v přehledu. Hradec Králové: Credit 2004: 230-231.
    15. www.accumetrics.com
    16. Aspirin-resistance, determined by Accumetrics Aspirin Test, linked to increased risk for adverse outcomes in routine stenting procedure. www.accumetrics.com
    17. Eikelboom JW, Hirsh J, Weitz JI et al. Aspirin Resistant Thromboxane Biosynthesis and the Risk of Myocardila Infarction, Stroke, or Cardiovascular Death in Patiens at High Risk for Cardiovascular Events. Circulation 2002; 105: 1650-1655. Go to original source... Go to PubMed...
    18. Gum PA, Mottle-Marchant K, Welsh PA et al. A prospective, blinded determination of the natural history of aspirin resistence among stable patiens with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965. Go to original source... Go to PubMed...
    19. Peters RJG, Shamir MR, Fox KAA et al. Effects of Aspirin Dose When Used Alone or in Combination With Clopidrogel in Patients With Acute Coronary Syndromes. Circulation 2003; 108: 1682-1687. Go to original source... Go to PubMed...
    20. Poulsen T, Mickley H, Licht P et al. Aspirin resistance and acute myocardial infarction. In: Abstracts book of XIX Nordic Congress of Cardiology.
    21. Grotemeyer KH. Two-year follow-up of aspirin responder and aspirin non responder. A pilot study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403. Go to original source... Go to PubMed...
    22. Mueller MR, Salat A, Stanul P et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-1007. Go to original source... Go to PubMed...
    23. Antithrombotics Trialist's Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 1999; 318: 759-764. Go to PubMed...
    24. Chen WH, Lee PY, Ng W Aspirin resistence in associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despote clopidrogel pretreatment. J Am Coll Cardiol 2004; 43: 1122-1126. Go to original source... Go to PubMed...
    25. Frossard M, Fuchs I, Leitner JM et al Platelet Function Predicts Myocardial damage in Patients With Acute Myocardial Infarction. Circulation 2004; 110: 1392-1397. Go to original source... Go to PubMed...
    26. Altman E, Cohen M, Bernink P et al. The TIMI Risk Score for unstable angina/non-ST elevation MI: a Method for prognostication and therapeutic decision making. JAMA 2000; 284: 835-842. Go to original source... Go to PubMed...
    27. Koh TW. Long-term clopidogrel therapy in the drug-eluting stent era: beyond CREDO and PCI-CURE. Eur Heart J 2004; 25: 1364-1365. Go to original source... Go to PubMed...
    28. Eriksson P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the "Emperor's New Clothes" revisited. Eur Heart J 2004; 25: 720-722. Go to original source... Go to PubMed...
    29. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med 2004; 164: 2106-2110. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.